Outcomes in COVID-19 proxalutamide studies
0
0.5
1
1.5+
ALL STUDIES
MORTALITY
VENTILATION
HOSPITALIZATION
VIRAL CLEARANCE
RCTS
RCT MORTALITY
PEER-REVIEWED
All
Early
Late
Proxalutamide for COVID-19
C19PROXALUTAMIDE.COM MAY 2022
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
death
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment
71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement
4 proxalutamide COVID-19 studies
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
0/75
1/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment
71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement
4 proxalutamide COVID-19 mortality results
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
97%
0.03 [0.00-0.47]
0/134
17/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
90%
0.10 [0.01-1.84]
0/75
5/102
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0043
Early treatment
95%
0.05 [0.01-0.40]
0/209
22/236
95% improvement
All studies
95%
0.05 [0.01-0.40]
0/209
22/236
95% improvement
2 proxalutamide COVID-19 mechanical ventilation results
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0043
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
91%
0.09 [0.03-0.27]
hosp.
3/134
35/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
86%
0.14 [0.03-0.60]
hosp.
2/75
19/102
Kintor (DB RCT)
50%
0.50 [0.15-1.65]
hosp.
4/365
8/365
Tau​2 ​ = 0.47, I​2 ​ = 53.4%, p = 0.002
Early treatment
81%
0.19 [0.07-0.54]
9/574
62/601
81% improvement
Cadegiani (DB RCT)
33%
0.67 [0.54-0.82]
hosp. time
423 (n)
355 (n)
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0001
Late treatment
33%
0.67 [0.54-0.82]
0/423
0/355
33% improvement
All studies
72%
0.28 [0.10-0.81]
9/997
62/956
72% improvement
4 proxalutamide COVID-19 hospitalization results
c19proxalutamide.com May 2022
Tau​2 ​ = 0.87, I​2 ​ = 80.5%, p = 0.019
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
death
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment
71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement
4 proxalutamide COVID-19 serious outcomes
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani (DB RCT)
45%
0.55 [0.49-0.62]
no recov.
423 (n)
355 (n)
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
45%
0.55 [0.49-0.62]
0/423
0/355
45% improvement
All studies
45%
0.55 [0.49-0.62]
0/423
0/355
45% improvement
1 proxalutamide COVID-19 recovery result
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Kintor (DB RCT)
74%
0.26 [0.13-0.51]
viral+
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Early treatment
74%
0.26 [0.13-0.51]
74% improvement
All studies
74%
0.26 [0.13-0.51]
74% improvement
1 proxalutamide COVID-19 viral clearance result
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
death
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment
71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement
4 proxalutamide COVID-19 Randomized Controlled Trials
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
0/75
1/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment
71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement
4 proxalutamide COVID-19 RCT mortality results
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
death
0/134
2/134
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.3
Early treatment
80%
0.20 [0.01-4.13]
0/134
2/134
80% improvement
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment
78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement
All studies
78%
0.22 [0.16-0.30]
45/557
173/489
78% improvement
2 proxalutamide COVID-19 peer reviewed trials
c19proxalutamide.com May 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT)
80%
0.20 [0.01-4.13]
death
0/134
2/134
Improvement, RR [CI]
Treatment
Control
McCoy (DB RCT)
97%
0.03 [0.00-0.47]
ventilation
0/134
17/134
McCoy (DB RCT)
91%
0.09 [0.03-0.27]
hosp.
3/134
35/134
Cadegiani (DB RCT)
63%
0.37 [0.02-8.85]
death
0/75
1/102
Cadegiani (DB RCT)
90%
0.10 [0.01-1.84]
ventilation
0/75
5/102
Cadegiani (DB RCT)
86%
0.14 [0.03-0.60]
hosp.
2/75
19/102
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/365
1/365
Kintor (DB RCT)
50%
0.50 [0.15-1.65]
hosp.
4/365
8/365
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/360
1/361
Kintor (DB RCT)
71%
0.29 [0.06-1.37]
hosp.
2/360
7/361
Kintor (DB RCT)
67%
0.33 [0.01-8.16]
death
0/346
1/347
Kintor (DB RCT)
92%
0.08 [0.00-1.36]
hosp.
0/346
6/347
Kintor (DB RCT)
74%
0.26 [0.13-0.51]
viral+
n/a
n/a
Cadegiani (DB RCT)
78%
0.22 [0.16-0.30]
death
45/423
171/355
Cadegiani (DB RCT)
79%
0.21 [0.15-0.30]
death
34/423
138/355
Cadegiani (DB RCT)
45%
0.55 [0.49-0.62]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT)
55%
0.45 [0.39-0.52]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT)
33%
0.67 [0.54-0.82]
hosp. time
423 (n)
355 (n)
proxalutamide COVID-19 outcomes
c19proxalutamide.com May 2022
Favors proxalutamide
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit